Ro, Hims/Hers, and Calibrate spend more on GLP-1 advertising in a week than most independent practices spend in a year. They have brand awareness, venture capital, and distribution infrastructure that independent practices cannot replicate. Trying to compete with them on price or convenience is a strategy for losing slowly.
A functional medicine practice in the mid-South learned this directly. They launched their GLP-1 program in 2024 with competitive pricing and a telehealth-first model. Their ads positioned on cost and access: easy to start, lower price than competitors, no in-person visit required. They generated patients. Their 90-day retention rate was 34 percent.
The patients they lost were leaving for exactly the reasons they had been attracted: someone offered a lower price, or a more convenient sign-up process, or a different platform with a promotion running. The practice had competed on the features that make patients easiest to lose.
The practices that build sustainable GLP-1 programs compete on something DTC cannot offer: clinical depth, a specific patient they serve particularly well, and a protocol that produces outcomes that a medication-dispensing platform structurally cannot. If a patient is interested only in the lowest price, that patient is not the right fit. If a patient is interested only in the drug without the clinical support, that patient is not the right fit. Accepting this is not a concession. It is a positioning decision that defines which patient base the practice is building.
GLP-1 Marketing: Why Positioning Against DTC Is the First Strategic Decision
Before building a GLP-1 marketing strategy, an independent practice needs to make an honest assessment: who are we for, and who are we not for?
DTC GLP-1 platforms are optimized for patients who want medication access with minimal friction, at the lowest available price, with no need for a substantive clinical relationship. These platforms are very good at what they do. A patient who fits that description will find a DTC platform, compare prices, and choose the lowest one. Competing for that patient requires continuously lowering prices or finding ways to make sign-up even more frictionless, a race that independent practices cannot win and should not enter.
The patient an independent practice is positioned to serve is different: someone who wants clinical oversight, not just a prescription. Someone who has tried weight loss approaches before and knows they need more than a drug. Someone who is managing comorbidities (metabolic syndrome, insulin resistance, thyroid dysfunction, hormone imbalance) that require a clinical eye alongside the GLP-1 protocol. Someone who is willing to invest in a program because they are investing in their health, not just trying a medication.
Marketing to this patient requires communicating what the practice offers that DTC does not. Not "we offer GLP-1 at a competitive price." That is DTC's territory. The message that works for the right patient is: "We treat the whole picture. The GLP-1 is one tool in a protocol built around your specific metabolic profile, not a prescription sent to your pharmacy after a 10-minute form submission."
This is not a marketing message that produces high lead volume or low CPL. It is a message that produces patients who are the right fit, and the right-fit patient has a dramatically higher retention rate and lifetime value than the price-shopper.
“From the Field: The practices that survive and grow in the GLP-1 space are the ones that have stopped trying to compete on price and convenience and started competing on who they genuinely help the most. That requires being honest about your clinical differentiation, your background, your protocol, your specific patient type, and marketing to that specifically. If you cannot articulate what makes your program different from signing up at a DTC platform, your patients cannot either, and they will leave when a cheaper option appears.”
Niche Down: The Differentiation That Separates Sustainable GLP-1 Programs
Simply offering telehealth and GLP-1 medications is not a differentiation in 2026. There are hundreds of practices offering exactly that. You are competing with DTC brands that have built the same offering at scale with superior technology. Without a real differentiation, "we offer telehealth GLP-1" is not a marketing message, it is a category description.
The differentiation that works is specific and builds on something the practice actually has: clinical background, a specific patient type, a protocol that goes deeper than medication management, or a clinical combination that DTC cannot replicate.
Differentiation Approaches That Work
Specialty-adjacent metabolic positioning. A functional medicine practice with expertise in hormone optimization, thyroid management, or metabolic syndrome can position GLP-1 as one component of a comprehensive metabolic health protocol. "We treat the hormonal and metabolic root causes alongside the GLP-1 protocol, not just the weight" differentiates immediately from platforms that manage the prescription only.
Specific patient type expertise. "We specialize in GLP-1 programs for patients who have tried other approaches and not seen lasting results" or "Our program is designed for patients managing metabolic syndrome with multiple comorbidities" speaks to a specific patient who recognizes themselves and is more likely to trust a practice that understands their situation than a generic weight loss platform.
Clinical oversight intensity. A program with monthly provider check-ins, regular metabolic panels, dose adjustments based on lab data, and a clinical team that responds to patient questions within 24 hours is meaningfully different from a platform that sends a refill without review. Making that clinical oversight visible, in the marketing, in the website content, in the onboarding process, communicates the value proposition clearly.
Physician background and specific expertise. A physician with board certification in endocrinology, obesity medicine, or functional medicine treating GLP-1 patients has a credential story that a nurse practitioner at a telehealth platform does not. That credential is a marketing asset when it is communicated specifically, not hidden in a bio paragraph.
Branding, case studies, and specific results stories matter even within these differentiating positions. Two practices can offer "comprehensive metabolic health" as a positioning and look completely identical in their marketing. The one with specific patient stories, documented outcomes, and a clinical voice that communicates genuine expertise will attract the right patient. The generic version will not.
Platform Restrictions and Compliance: GLP-1 Advertising Constraints
GLP-1 advertising requires a compliance filter at every step of campaign development. Meta's policies on weight loss advertising are among the most aggressively enforced in healthcare. Google is more permissive for GLP-1 specifically, but still requires careful copy management.
Meta Advertising Restrictions for GLP-1
Meta's weight loss advertising policies prohibit:
- Before/after imagery showing body transformation in ad creative
- Copy that implies or promises specific weight loss outcomes ("lose 30 pounds in 12 weeks")
- Imagery that negatively characterizes body weight or size as shameful or problematic
- Targeting based on inferred health conditions, including obesity
The compliant approach for GLP-1 Meta advertising: lead with health outcomes, not weight loss. "Feel more energy, reduce metabolic risk factors, and take control of your health with our medically supervised program" addresses the patient's underlying motivations without triggering weight loss policy restrictions. "Lose the weight you have been struggling with" will get the ad flagged.
Clinical positioning language, "medically supervised," "physician-led," "metabolic health program", keeps the focus on clinical care rather than appearance-based outcomes, which both avoids policy violations and appeals to the right patient type.
Google Advertising for GLP-1
Google allows GLP-1 and semaglutide advertising for certified healthcare providers but requires LegitScript certification for practices advertising prescription medications online in the United States. This certification requires verification of licensure and adherence to advertising standards. Practices that have not obtained LegitScript certification will have their prescription medication ads disapproved.
Google copy for GLP-1 can reference the medication by name ("semaglutide program," "GLP-1 treatment") where policy-compliant certification is in place. Copy that makes specific weight loss claims ("lose up to X pounds") is inadvisable regardless of platform. Copy that leads with clinical oversight, medical supervision, and patient evaluation is safer and more aligned with the patient type the practice is trying to attract.
GLP-1 Patient Acquisition: Payment Flexibility and Insurance Navigation
Insurance coverage for GLP-1 medications prescribed for weight management is inconsistent and actively contested. As of 2025-2026, many commercial insurance plans cover semaglutide for type 2 diabetes but not for weight loss specifically. Medicare covers GLP-1 drugs for cardiovascular risk reduction in qualifying patients but not for weight management alone. Medicaid coverage varies by state.
Patients researching GLP-1 programs have insurance coverage as a primary anxious question. "Does insurance cover Ozempic for weight loss?" is one of the highest-volume search queries in this category. Practices that address this question directly, and that offer multiple payment pathways, convert at meaningfully higher rates than practices that leave the insurance question unanswered or present a single payment option.
The payment flexibility framework that works:
Insurance navigation support. For patients with commercial plans that may cover GLP-1 for qualifying diagnoses, offer to help with prior authorization and coverage verification. This requires clinical staff time but produces patients who are paying in-network and are more likely to continue because their financial barrier is lower.
Cash-pay transparent pricing. For patients whose insurance does not cover GLP-1 for weight management, a clear cash-pay price for the program and medication options (including compounded semaglutide where legally available, with appropriate clinical disclosure) addresses the accessibility concern directly. Hiding pricing until the consultation is a conversion barrier that costs leads.
HSA/FSA confirmation. GLP-1 medications prescribed for qualifying medical conditions may be HSA/FSA eligible. Confirming this explicitly in marketing and on landing pages addresses a specific patient question and removes a financial barrier.
Subscription pricing with flexible cancellation. A monthly program subscription with transparent pricing and no long-term commitment reduces the risk in the patient's mind. The fear of being locked into an expensive program that does not work is a real barrier for patients who have invested in weight loss approaches before.
LTV and Retention: The Math That Makes GLP-1 Marketing Work
GLP-1 is a subscription business. A patient on a GLP-1 program for 12 months generates $3,000 to $7,000 or more in revenue depending on the program structure, medication costs, and ancillary services. A patient who discontinues at month two generates $600 to $1,200.
The acquisition cost that looks acceptable changes completely depending on which patient type the practice is measuring against.
A $400 acquisition cost that looks expensive against a two-month LTV of $800 (50 percent margin on two months) looks entirely different against a 12-month LTV of $5,000. Practices that evaluate GLP-1 marketing performance on first-visit or first-month revenue will consistently underinvest, because the math does not work until the full LTV picture is visible.
This math also means that retention investment is marketing investment. Clinical oversight quality, patient communication cadence, dose management, and the responsiveness of the clinical team are all factors in whether a patient stays on program for two months or twelve. A practice that underinvests in retention infrastructure and spends aggressively on acquisition is running a leaking bucket. The marketing spend that generates patients does not matter if the program does not retain them.
Practice Growth Co works with GLP-1 practices to track patient retention rate and LTV specifically because the acquisition-cost-only view of marketing performance leads practices to make decisions that look rational in the short term and are damaging over 12 months.
SEO and Informational Content: The Quiet Channel That Compounds
GLP-1 patient intent starts informational for a large segment of the addressable market. Patients searching "how does semaglutide work," "Ozempic vs. Wegovy for weight loss," "GLP-1 side effects," and "does insurance cover GLP-1" are in the early stages of their decision process. They are not yet ready to submit a form or call for a program consultation.
Practices that own these informational queries through content capture patients at the moment they start researching and build authority during the months those patients move from curiosity to consideration to commitment. The practice that answered their question about semaglutide side effects six months ago is already in their trust consideration set when they are ready to start a program.
This SEO investment does not produce immediate, visible ROI. The content takes months to rank, and the patients it captures are often 60 to 120 days from conversion. Committing to this channel requires accepting that it works quietly in the background and compounds over time, without the immediate feedback loop that paid advertising provides.
The practices that build topical authority in GLP-1 content, physician-authored posts about metabolic health, FAQs that answer specific insurance and medication questions, comparison content that addresses "Ozempic vs. Wegovy vs. Mounjaro", create a durable search presence that paid advertising cannot replicate and competitors cannot easily displace. For the detailed SEO content strategy and topical cluster approach for GLP-1 practices, the seo for GLP-1 practices cluster post covers the full framework.
FAQ: GLP-1 Marketing Questions
How much should a GLP-1 practice spend on marketing per month?
A single-location practice launching a GLP-1 program typically invests $3,000 to $6,000 per month in paid media during the launch phase, with that investment evaluated against program LTV rather than first-visit revenue. Practices that have established clinical differentiation and positive patient outcomes can invest more aggressively because their retention rate justifies the acquisition cost. Practices still refining their program should invest more conservatively until retention data is available to validate the LTV assumptions.
Is Google Ads or Meta Ads better for GLP-1 patient acquisition?
Google Ads for specific search queries (patients actively searching for GLP-1 programs, semaglutide treatment, or metabolic health programs) typically produces higher-intent leads with better initial conversion rates. Meta Ads, used with compliant copy that avoids weight loss outcome claims, can produce higher lead volume at lower CPL but with lower initial intent. For practices with strong clinical positioning and the staff capacity to nurture lower-intent leads, both channels can contribute. For practices with limited follow-up capacity, Google Ads' higher-intent traffic is typically the better starting point.
How do I differentiate my GLP-1 program from telehealth platforms like Ro or Hims?
By being specific about what you offer that they do not. Generic statements ("we provide personalized care") are not differentiators when every practice says the same thing. The differentiation has to be specific: your clinical background in metabolic medicine, your protocol's components beyond medication management (hormone optimization, lifestyle coaching, metabolic panels), your physician's specific training, or your approach to patients with complex metabolic comorbidities. The patient you are trying to attract should recognize themselves in your specific story, not in a generic description of comprehensive care.
What is a realistic retention rate for a GLP-1 program?
12-month retention rates for GLP-1 programs vary significantly by program structure, patient selection, and retention infrastructure. Medication-only programs with minimal clinical touch see 30 to 45 percent 12-month retention. Programs with regular provider check-ins, lab monitoring, dose adjustment, and lifestyle support see 55 to 70 percent retention. The gap between those retention rates, compounded over 24 months across a patient base of 100 patients, is the difference between a profitable program and a marginal one.
Should I advertise specific GLP-1 medications by name (Ozempic, Wegovy, Mounjaro)?
On Google, naming these medications in ad copy and landing pages is generally permissible for certified healthcare providers with LegitScript certification, and it is strategically valuable, these are high-volume search terms with strong patient intent. On Meta, advertising specific prescription medications by brand name is subject to healthcare advertising restrictions and requires more careful review. Including medication names in website content for SEO purposes is straightforward and valuable. Including them in paid advertising requires platform-specific compliance review.
GLP-1 programs that grow sustainably are built on clinical differentiation, a specific patient they serve best, and retention infrastructure that makes the acquisition cost economics work. Practice Growth Co builds patient acquisition systems for GLP-1 and metabolic health practices that attract the right patient and keep them. Book a Strategy Call →
Mike Funkhouser is the founder of Practice Growth Co, a healthcare-focused patient acquisition agency specializing in Google Ads, Meta Ads, SEO, and AI search optimization for specialty medical practices. He has helped plastic surgery groups, orthopedic clinics, med spas, and specialty practices build scalable, measurable patient acquisition systems across the US.
Sources and Citations
- U.S. Food and Drug Administration — Semaglutide Approved Uses and Prescribing Information — FDA-approved indications for GLP-1 medications relevant to marketing compliance
- LegitScript — Certification Requirements for Healthcare Advertisers — Certification requirements for advertising prescription medications on major platforms
- Meta for Business — Weight Loss and Body Image Advertising Policies — Platform policy for weight loss program advertising restrictions
- Centers for Medicare and Medicaid Services — GLP-1 Coverage Guidance — Insurance coverage rules for GLP-1 medications under Medicare and Medicaid
- Practice Growth Co — GLP-1 Program Patient Acquisition and Retention Data — Proprietary Practice Growth Co campaign data, 2025-2026